| Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma TK Choueiri, T Powles, M Burotto, B Escudier, MT Bourlon, B Zurawski, ... New England Journal of Medicine 384 (9), 829-841, 2021 | 1202 | 2021 |
| Enzalutamide with standard first-line therapy in metastatic prostate cancer ID Davis, AJ Martin, MR Stockler, S Begbie, KN Chi, S Chowdhury, ... New England Journal of Medicine 381 (2), 121-131, 2019 | 1195 | 2019 |
| Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised … RJ Motzer, BI Rini, DF McDermott, OA Frontera, HJ Hammers, ... The Lancet Oncology 20 (10), 1370-1385, 2019 | 704 | 2019 |
| Phase III trial of PROSTVAC in asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer JL Gulley, M Borre, NJ Vogelzang, S Ng, N Agarwal, CC Parker, DW Pook, ... Journal of Clinical Oncology 37 (13), 1051, 2019 | 228 | 2019 |
| 696O_PR Nivolumab+ cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial TK Choueiri, T Powles, M Burotto, MT Bourlon, B Zurawski, VMO Juárez, ... Annals of Oncology 31, S1159, 2020 | 151 | 2020 |
| Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor … GP Risbridger, RA Taylor, D Clouston, A Sliwinski, H Thorne, S Hunter, ... European Urology 67 (3), 496-503, 2015 | 148 | 2015 |
| A preclinical xenograft model of prostate cancer using human tumors MG Lawrence, RA Taylor, R Toivanen, J Pedersen, S Norden, DW Pook, ... Nature protocols 8 (5), 836-848, 2013 | 120 | 2013 |
| ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Enzalutamide with standard first-line therapy in metastatic prostate … ID Davis, AJ Martin, MR Stockler, S Begbie, KN Chi, S Chowdhury, ... N Engl J Med 381 (2), 121-131, 2019 | 109 | 2019 |
| Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer KN Chi, D Rathkopf, MR Smith, E Efstathiou, G Attard, D Olmos, JY Lee, ... Journal of Clinical Oncology 41 (18), 3339-3351, 2023 | 103 | 2023 |
| Patient-derived models of abiraterone-and enzalutamide-resistant prostate cancer reveal sensitivity to ribosome-directed therapy MG Lawrence, D Obinata, S Sandhu, LA Selth, SQ Wong, LH Porter, ... European urology 74 (5), 562-572, 2018 | 98 | 2018 |
| A bioengineered microenvironment to quantitatively measure the tumorigenic properties of cancer-associated fibroblasts in human prostate cancer AK Clark, AV Taubenberger, RA Taylor, B Niranjan, ZY Chea, E Zotenko, ... Biomaterials 34 (20), 4777-4785, 2013 | 76 | 2013 |
| Regulation of the transcriptional coactivator FHL2 licenses activation of the androgen receptor in castrate-resistant prostate cancer MJ McGrath, LC Binge, A Sriratana, H Wang, PA Robinson, D Pook, ... Cancer research 73 (16), 5066-5079, 2013 | 66 | 2013 |
| A preclinical xenograft model identifies castration-tolerant cancer-repopulating cells in localized prostate tumors R Toivanen, M Frydenberg, D Murphy, J Pedersen, A Ryan, D Pook, ... Science translational medicine 5 (187), 187ra71-187ra71, 2013 | 65 | 2013 |
| A pro‐tumourigenic loop at the human prostate tumour interface orchestrated by oestrogen, CXCL12 and mast cell recruitment SJ Ellem, RA Taylor, L Furic, O Larsson, M Frydenberg, D Pook, ... The Journal of pathology 234 (1), 86-98, 2014 | 58 | 2014 |
| CheckMate 214 investigators. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety … RJ Motzer, BI Rini, DF McDermott, O Arén Frontera, HJ Hammers, ... Lancet Oncol 20 (10), 1370-1385, 2019 | 51 | 2019 |
| Breaking through a roadblock in prostate cancer research: an update on human model systems R Toivanen, RA Taylor, DW Pook, SJ Ellem, GP Risbridger The Journal of steroid biochemistry and molecular biology 131 (3-5), 122-131, 2012 | 48 | 2012 |
| Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an … CJ Sweeney, AJ Martin, MR Stockler, S Begbie, L Cheung, KN Chi, ... The Lancet Oncology 24 (4), 323-334, 2023 | 46 | 2023 |
| Establishment of primary patient‐derived xenografts of palliative TURP specimens to study castrate‐resistant prostate cancer MG Lawrence, DW Pook, H Wang, LH Porter, M Frydenberg, ... The Prostate 75 (13), 1475-1483, 2015 | 43 | 2015 |
| The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology GP Risbridger, AK Clark, LH Porter, R Toivanen, A Bakshi, NL Lister, ... Nature communications 12 (1), 5049, 2021 | 42 | 2021 |
| Updated overall survival outcomes in ENZAMET (ANZUP 1304), an international, cooperative group trial of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC). ID Davis, AJ Martin, RR Zielinski, A Thomson, TH Tan, S Sandhu, ... Journal of Clinical Oncology 40 (17_suppl), LBA5004-LBA5004, 2022 | 41 | 2022 |
